Valuation: Viatris Inc.

Market Cap 18.64B 16.09B 15.1B 13.75B 25.86B 1,782B 26.22B 177B 69.36B 893B 69.99B 68.47B 2,970B P/E 2026 *
77.1x
P/E 2027 * 30.6x
Enterprise Value 30.71B 26.51B 24.87B 22.65B 42.59B 2,936B 43.18B 292B 114B 1,471B 115B 113B 4,893B EV / Sales 2026 *
2.08x
EV / Sales 2027 * 1.98x
Free-Float
91.44%
Yield 2026 *
3.13%
Yield 2027 * 3.22%
1 day+0.86%
1 week-0.89%
Current month-8.37%
1 month-8.70%
3 months-2.46%
6 months+5.20%
Current year+32.95%
1 week 13.74
Extreme 13.742
14.2
1 month 13.74
Extreme 13.742
15.73
Current year 10.49
Extreme 10.49
15.73
1 year 8.05
Extreme 8.05
15.73
3 years 6.26
Extreme 6.262
15.73
5 years 6.26
Extreme 6.262
15.73
10 years 6.26
Extreme 6.262
15.73
Manager TitleAgeSince
Chief Executive Officer 63 31/03/2023
Director of Finance/CFO 59 07/05/2026
Chief Tech/Sci/R&D Officer - 14/12/2023
Director TitleAgeSince
Director/Board Member 78 15/11/2020
Director/Board Member 78 15/11/2020
Director/Board Member 62 15/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%-0.89% - - 18.64B
+0.25%-3.96%+68.73%+120.06% 1,055B
+0.78%+0.21%+48.53%+50.78% 632B
+0.35%+0.95%+21.11%+66.86% 442B
+0.73%-2.93%+39.88%+40.40% 351B
+0.72%-1.27%+23.99%+39.01% 290B
+1.40%-1.41%-0.52%+9.56% 243B
+1.00%+0.52%+41.46%+58.95% 227B
-0.67%-5.34%-16.32%-53.52% 200B
+0.40%+4.40%+17.36%+81.59% 172B
Average +0.73%-1.44%+27.14%+45.97% 401.39B
Weighted average by Cap. +0.78%-1.87%+39.43%+64.44%

Financials

2026 *2027 *
Net sales 14.78B 12.76B 11.97B 10.9B 20.5B 1,413B 20.79B 140B 55B 708B 55.5B 54.3B 2,355B 15.03B 12.97B 12.17B 11.09B 20.85B 1,437B 21.13B 143B 55.91B 720B 56.42B 55.2B 2,395B
Net income -27.26M -23.53M -22.08M -20.11M -37.81M -2.61B -38.33M -259M -101M -1.31B -102M -100M -4.34B 340M 293M 275M 251M 471M 32.5B 478M 3.23B 1.26B 16.28B 1.28B 1.25B 54.16B
Net Debt 12.07B 10.42B 9.77B 8.9B 16.74B 1,154B 16.97B 115B 44.89B 578B 45.3B 44.32B 1,922B 11.08B 9.56B 8.97B 8.17B 15.37B 1,059B 15.58B 105B 41.22B 531B 41.59B 40.69B 1,765B
Logo Viatris Inc.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
30,000
Date Price Change
16/08/26 13.96 +0.22%
14/08/26 €13.93 -1.57%
13/08/26 €14.15 +0.21%
12/08/26 €14.12 +0.43%
11/08/26 €14.06 -0.17%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
16.23USD
Average target price
18.50USD
Spread / Average Target
+13.99%

Quarterly revenue - Rate of surprise